Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Monoclonal Antibodies (MAbs) Market Expected to Grow Between 2025 And 2029?

The market size of monoclonal antibodies (MAbs) has experienced a swift expansion in the past few years. The growth is projected to continue from $234.37 billion in 2024 to $261.66 billion in 2025, with a compound annual growth rate (CAGR) of 11.6%. Factors contributing to the growth during the historic period include the rise in chronic diseases, increased investment in research and development, heightened awareness of MAbs, and an aging population.

What Growth Rate Is Anticipated for the Monoclonal Antibodies (MAbs) Market in the Coming Years?

The market for monoclonal antibodies (MAbs) is anticipated to experience swift expansion in the forthcoming years, with estimations predicting it to reach a value of $424.24 billion by 2029, corresponding to a compound annual growth rate (CAGR) of 12.8%. The predicted upsurge during the forecast period is tied to growth factors like the widening scope of therapeutic indications, the rise in personalized medicine, the surge in biosimilars and generics, combination therapies, readiness for pandemics, and increased investment in biopharmaceuticals. Key trends during this period focus on the progress in immunotherapy, the adoption of subcutaneous administration, the evolution of next-generation antibodies, the introduction of subcutaneous formulations, the integration with digital health, and advancements in biotechnology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2554&type=smp

Who Are the Leading Companies in the Monoclonal Antibodies (MAbs) Market?

Major companies operating in the monoclonal antibodies (MAbs) market include Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals plc, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., Troikaa Pharmaceuticals Ltd., CD BioSciences Inc., Kanto Corporation, Molecular Depot LLC, Epigentek Group Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Diagnostic BioSystems Inc., Tonbo Biosciences Inc., Abraxis LLC, GlaxoSmithKline plc

What Are the Key Drivers of the Monoclonal Antibodies (MAbs) Market?

The growth of the monoclonal antibody market is being propelled by the rising prevalence of cost-effective biosimilar monoclonal antibodies. The objective of these biosimilars is to manage the growing healthcare costs and address the financial strain from patients and governments to decrease medication expenses and enhance treatment accessibility. Biosimilars, developed to exhibit comparable properties to an already approved biological drug, cost about 20%-25% less than the original biologic drug. The reduced number of clinical trials required for a biosimilar, compared to an original biologic drug, results in a lower cost for the biosimilar drug. In India, a recent policy named the ‘Guidelines on Similar Biologics’, formulated by the Central Drugs Standard Control Organization (CSDCO), is anticipated to significantly enhance the local biosimilar drugs industry.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2554&type=smp

What Are the Key Market Segments in the Monoclonal Antibodies (MAbs) Industry?

The monoclonal antibodies (MAbs) market covered in this report is segmented –

1) By Source: Murine, Chimeric, Humanized, Human

2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAs), Neuropharmacological, Cardiovascular And Cerebrovascular, Other Applications

3) By End Users: Hospitals, Private Clinics, Research Institute

Subsegments:

1) By Murine: Fully Murine MAbs, Murine-Derived MAbs

2) By Chimeric: Chimeric MAbs With Murine Variable Regions, Chimeric MAbs With Human Constant Regions

3) By Humanized: Humanized MAbs With Minor Murine Components, Fully Humanized MAbs

4) By Human: Fully Human MAbs, Engineered Human MAbs

What Are the Latest Trends in the Monoclonal Antibodies (MAbs) Market?

In recent years, a variety of strategic actions have been implemented within the monoclonal antibody market. Major market players are engaging in targeted acquisitions of start-ups and medium-sized businesses to enhance their product and service offerings. These tactics, which include strategic collaborations, acquisitions, and partnership agreements, allow vendors to amplify their existing product range and expand their geographical footprint. For example, in March 2022, Sanofi S.A., a pharmaceutical and healthcare company from France, announced a strategic alliance with Seagen Inc., an American pharmaceutical firm specializing in innovative monoclonal antibody-based cancer therapies. As part of the agreement, the monoclonal antibody (mAb) and antibody-drug conjugate (ADC) technologies exclusive to Seagen and Sanofi will be leveraged to create, develop, and commercialize ADCs targeting up to three types of cancer. Additionally, Boehringer Ingelheim, a research-focused pharmaceutical enterprise from Germany, has joined forces with MabGenesis, Inc., a Japanese biopharmaceutical firm specializing in the development of monoclonal antibody drugs treating human diseases. This partnership has yielded innovative therapeutic monoclonal antibodies for various diseases and paved the path for strategic research and development approaches. Companies within the sector are actively restructuring their portfolios and chasing lucrative inorganic growth opportunities. Also, mergers and acquisitions are being driven by improved corporate financial health, liquid debt markets, and persistently favorable interest rates worldwide.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

What Are the Key Regional Markets in the Monoclonal Antibodies (MAbs) Industry?

The countries covered in the monoclonal antibodies (MABS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2554

This Report Delivers Insight On:

1. How big is the monoclonal antibodies (mabs) market, and how is it changing globally?

2. Who are the major companies in the monoclonal antibodies (mabs) market, and how are they performing?

3. What are the key opportunities and risks in the monoclonal antibodies (mabs) market right now?

4. Which products or customer segments are growing the most in the monoclonal antibodies (mabs) market?

5. What factors are helping or slowing down the growth of the monoclonal antibodies (mabs) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model